Innodem Neurosciences, a Montreal, Canada-based digital biomarking technology company, closed a USD6M Series A financing round.
The round was led by Morningside Ventures.
The company intends to use the funds for the development and commercialization of technology.
Led by Dr. de Villers-Sidani, cognitive neurologist, main founder, Chief Executive Officer & Chief Scientific Officer, and Marc Reeves, co-founder & Chief Business Officer, Innodem Neurosciences is advancing proprietary, patented, digital biomarking technology of neurodegenerative diseases such as Multiple Sclerosis (MS), Alzheimer’s disease, Parkinson’s disease and related disorders, Frontotemporal Dementia and related disorders and Cancer-Related Cognitive Impairment.
The company’s mobile software technology is embodied in an application that turns a tablet or a smartphone into a device capable of capturing Eye Movement Biomarkers (EMBs) and Gaze Mapping Biomarkers (GMBs) accurately within minutes in order to assist a clinician’s diagnosis. Current and future clinical validation trials will provide EMB & GMB data to Innodem’s fully integrated HIPAA/PIPEDA compliant data management pipeline leveraging the latest deep learning technology.